If this box remains here for more than 30 seconds, click this link to try again.
Industries
Functions
Home » Products & Services » Best Practice Database » Patient Focused Services » Patient Support Programs
Download FREE Excerpt
7 Info Graphics
7 Data Graphics
70 Metrics
2 Narratives
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Buy Now
STUDY OVERVIEW Patient assistance programs have become important ways for pharma to help patients navigate expensive therapies or new products that are pending coverage by payers. Fast start programs are typically patient assistance provided for new drugs with pending coverage approval. Bridge programs are patient assistance provided by drug makers to reduce or eliminate costs for eligible individuals. Best Practices, LLC prepared this research to identify and spotlight current trends and future directions of bridge assistance and fast start programs supporting new biopharmaceutical product programs.
The study probes the prevalence and impact of such bridge programs and examines their role during new product introduction. The research also evaluates bridge programs' role in the context of overall pull through services to help patients get quickly and effectively started on new medicines. KEY TOPICS
Nine benchmarking field studies that included more than 100 companies were used to probe patient assistance programs for this analysis
Industries Profiled: Pharmaceutical; Health Care; Consumer Products; Biotech; Medical Device; Manufacturing; Diagnostic; Biopharmaceutical; Clinical Research; Laboratories Companies Profiled: Merck; Merck Serono; Novo Nordisk; Novartis; Lundbeck; CSL Behring; Johnson & Johnson; Biogen; Allergan; Alcon; Bayer; Roche; Sunovion; ViiV Healthcare; Ipsen; Sanofi; AstraZeneca; Takeda Pharmaceuticals; OTSUKA; Genzyme
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.
Top